Skip to main content

Table 4 Subgroup analysis of mOS, mPFS, and ORR of Pembrolizumab combined with chemotherapy in SCLC

From: The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Subgroups

mOS

mPFS

ORR

No. of studies

ES (95% CI)

P

I2

No. of studies

ES (95% CI)

P

I2

No. of studies

ES (95% CI)

P

I2

Total

            

Study design

 Noncomparative Open-label study

4

9.0 (7.1-10.9)

0.234

29.70%

5

4.3 (1.7-7.0)

0

89.00%

5

32.1% (7.3-56.9%)

0

94.20%

 Randomized control study

1

10.8 (9.2-12.9)

-

-

1

4.5 (4.3-5.4)

NR

NR

1

-

-

-

Chemotherapy drug

 Platinum plus etoposide

4

9.7 (7.7-11.7)

0.072

57.10%

5

4.0 (1.8-6.3)

0

93.30%

5

41.9% (11.4-72.3%)

0

97.60%

 Platinum plus etoposide and paclitaxel

1

9.1 (6.5–15.0)

-

-

1

5.0 (2.7–6.7)

NR

NR

1

23.10% (6.9-39.3%)

-

-

Clinical setting

 Q3w, 200 mg, more than 30 cycles

2

10.4 (8.9-11.9)

0.45

0.00%

2

3.0 (0.0-6.0)

0

97.70%

2

39.34% (0.22–93.33%)

0.082

60.00%

 Q3w, 200 mg, 16cycles

2

19.8 (0-49.2)

0.053

73.20%

2

11.8 (1.3-22.3)

0.016

82.90%

2

46.26% (0.85-97.21%)

0

97.80%

 Q2w, 20 mg/kg, 48 cycles

-

-

-

-

1

1.9 (1.7-5.9)

NR

NR

1

33.3% (14.5-52.2%)

-

-

 Q3w, 175 mg/m2, 5 cycles

1

9.1 (6.5-15.0)

-

-

1

5.0 (2.7-6.7)

NR

NR

1

23.1% (6.9-39.3%)

-

-

SCLC phase

 ES-SCLC

4

9.5 (8.3-10.7)

0.315

15.40%

5

3.7 (1.9-5.6)

0

92.50%

5

30.8% (0.7-61.0%)

0

97.40%

 LS-SCLC

1

39.5 (8.0–71.0)

-

-

1

19.7 (8.8-30.5)

-

NR

1

78.79% (64.84-92.74%)

-

-

Study phase

 I

1

8.4 (6.7-10.1)

-

-

2

4.0 (0.1-7.9)

-

-

2

22.8% (5.2-40.3%)

0.113

60.20%

 II

2

9.5 (7.3-11.6)

0.842

0.00%

2

3.1 (0.4–5.8)

0.001

90.80%

2

15.2% (4.1-26.3%)

0.208

37.00%

 III

1

10.8 (9.2-12.9)

-

-

1

4.5 (4.3-5.4)

-

-

1

70.6% (64.7-76.52)

-

-

 I/II

1

39.5 (8.0-71.0)

-

-

1

19.7 (8.8-30.5)

-

-

1

78.79% (64.84-92.74%)

-

-

Median age

 ≤ 65 years old

3

9.9 (6.8-12.9)

0.03

71.40%

4

4.9 (2.5-7.2)

0.131

56.20%

4

49.8% (20.0-79.5%)

0

96.20%

 > 65 years old

2

9.5 (7.3-11.6)

0.842

0.00%

2

3.1 (0.4–5.8)

0.001

90.80%

2

15.2% (4.1-26.3%)

0.208

37.00%

Region

 America

4

9.7 (7.7-11.7)

0.072

57.10%

5

4.0 (1.8-6.3)

0

93.30%

5

41.9% (11.4-72.3%)

0

97.60%

 Korea

1

9.1 (6.5–15.0)

-

-

1

5.0 (2.7–6.7)

NR

NR

1

23.10% (6.9-39.3%)

-

-

Whether combine with radiation therapy

 No

3

10.2 (8.8-11.6)

0.644

0.00%

4

3.2 (1.1-5.2)

0

93.60%

4

34.23% (6.94–69.30%)

0

97.70%

 Yes

2

19.8 (0-49.2)

0.053

73.20%

2

11.8 (1.3–22.3)

0.016

82.90%

2

46.26% (0.085-97.21%)

0

97.80%

  1. Abbreviations: ES-SCLC extensive-stage small cell lung cancer, ES effect size, LS-SCLC limited-stage small cell lung cancer, ORR objective response rate, OS overall response, PFS progression-free survival, 95% CI 95% confidence interval
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us